Vesicular Formulation for Controlled Release Olanzapine
Mayssa Abdel Hady Mohamed;
Abstract
Olanzapine is a third generation atypical antipsychotic approved by the Food
and Drug Administration (FDA) in 1996. Olanzapine is used to treat
schizophrenia and delirium and significantly improves both the positive and
negative symptoms of schizophrenia
and Drug Administration (FDA) in 1996. Olanzapine is used to treat
schizophrenia and delirium and significantly improves both the positive and
negative symptoms of schizophrenia
Other data
| Title | Vesicular Formulation for Controlled Release Olanzapine | Other Titles | صياغة عقار الأولانزابين فى صورة حويصلات ممتدة المفعول | Authors | Mayssa Abdel Hady Mohamed | Keywords | Vesicular Formulation for Controlled Release Olanzapine | Issue Date | 2011 | Description | Olanzapine is a third generation atypical antipsychotic approved by the Food and Drug Administration (FDA) in 1996. Olanzapine is used to treat schizophrenia and delirium and significantly improves both the positive and negative symptoms of schizophrenia |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.